Home » Markets » German biotech firm says its coronavirus vaccine will be ready for approval by December
German biotech firm says its coronavirus vaccine will be ready for approval by December
Coronavirus vaccine will likely come in early 2021: Dr. Nicole Saphier
Fox News medical contributor Dr. Nicole Saphier says she’s optimistic America will have many more coronavirus treatment options going into flu season in the fall.
BERLIN—The German biotech firm that has partnered with Pfizer Inc. to develop a coronavirus vaccine is confident it will be ready to seek regulatory approval by the end of the year, according to its chief executive.
Continue Reading Below
Several hundred million doses could be produced even before approval, and over 1 billion by the end of 2021, BioNTech SE co-founder and CEO Dr. Ugur Sahin told The Wall Street Journal.
BioNTech, originally a cancer-treatment biotech company, is one of 17 firms world-wide that have started human trials on a vaccine against Covid-19. The company, based in the city of Mainz and listed on the Nasdaq stock exchange, was founded in 2008 by Dr. Sahin and his wife, Dr. Özlem Türeci, both the children of Turkish immigrants.
BIONTECH AND PFIZER'S CORONAVIRUS VACCINE SHOWS POTENTIAL IN HUMAN TRIAL
The vaccine BioNTech is developing uses experimental technology known as messenger RNA, or mRNA. Pending approval by authorities, BioNTech expects to begin the final stage of the testing process, known as Phase 3 trials, at the end of July. These would see 30,000 people take part in a randomized study of the vaccine that is expected to be completed by the end of the year, when the company would seek market approval from regulators across the globe.